站在"十五五"新程待启的关键时点，如何看待2026年的经济形势？2026年经济工作怎么干？新京报贝壳 财经推出《看2026：十五五·启新程》专题报道，汇聚监管部门、知名学者和领军企业家，解读政策脉 络，洞察趋势变化。2026，我们携手出发。 对于企业而言，针对中央经济工作会议提出的持续扩大内需等议题会有哪些举措？2026年有哪些战略发 展目标？新京报贝壳财经记者就此采访了博雅生命董事长李诣书。 新京报贝壳财经：中央经济工作会议提出持续扩大内需、优化供给，做优增量、盘活存量，因地制宜发 展新质生产力，对此，博雅生命会有哪些具体举措？ 李诣书：中央经济工作会议提出的"持续扩大内需、优化供给，做优增量、盘活存量，因地制宜发展新 质生产力"等政策导向，不仅是对国家宏观经济的战略部署，更是为生物医药、细胞治疗与再生医学这 一战略性新兴产业指明了高质量发展的核心路径。博雅生命作为一家在细胞科技领域深耕了16年的全产 业链企业，我们始终坚持服务国家大局，将企业战略主动融入"健康中国2030"的宏伟蓝图中，致力于通 过技术创新将生物制造打造成典型的"新质生产力"。面对新的政策机遇，博雅生命将会从以下三个维度 落实企业的战略举 ...

Core Insights - The company, Kaineng Health, is focusing on both water purification and the broader health industry, implementing a dual-driven development strategy that includes deepening its water purification business and expanding into cell technology [2][10] - Kaineng Health has undergone significant digital transformation, achieving a high level of automation and smart manufacturing, which has positioned it as a leader in the industry [3][5] - The company is actively building its own brand to capture service revenue and user data, which will help create a comprehensive health ecosystem [6][7] Digital Transformation - Kaineng Health has transitioned from traditional manufacturing to smart manufacturing, introducing automated production lines and digital systems that minimize human intervention [3][4] - The company has established a digital solutions output company, showcasing its expertise in supply chain management and digitalization to other industries [5] - By 2025, Kaineng Health plans to fully integrate AI technology into its manufacturing processes for further efficiency improvements [5] Brand Development and Market Expansion - Kaineng Health is leveraging its established supply chain to enhance its own brand, which is crucial for generating long-term service revenue [6][7] - The company has made strategic acquisitions, including a U.S. brand, to penetrate the North American market and plans to establish a local production base [6][7] - Kaineng Health's products are sold in over 100 countries, with more than 60% of revenue coming from developed markets [7] Financial Performance and Strategy - Kaineng Health has maintained an average annual revenue of approximately 1.6 billion yuan over the past three years, with a payout ratio exceeding 70% [8] - The company is committed to innovation and exploring new business avenues, particularly in cell technology, which has been a focus of investment despite previous challenges [8][9] - Recent announcements indicate plans for establishing subsidiaries in the cell industry and acquiring related companies to bolster growth [10]

Core Viewpoint - The company, Kaineng Health, is actively expanding its business into the cell technology sector through strategic acquisitions and investments, aiming to establish a second growth curve alongside its core water purification business [2][12]. Group 1: Business Expansion and Strategy - Kaineng Health has signed a framework agreement to acquire all equity and assets of several companies related to cell technology from Yuanneng Group, aiming to enhance its investment layout in the cell industry [2]. - The company is implementing a dual-driven development strategy, focusing on both its water purification business and the emerging cell technology sector [2][12]. - Kaineng Health plans to establish a wholly-owned subsidiary in Hainan or Hunan for cell industry operations and acquisitions, with a registered capital of 100 million yuan [12]. Group 2: Technological Advancements - Kaineng Health has upgraded its manufacturing capabilities to smart manufacturing, achieving recognition as a "2025 Excellent Smart Factory" by the Ministry of Industry and Information Technology [5]. - The company has established an independent digital solution output company, sharing its supply chain management experience and digital solutions with other industries [6]. Group 3: Brand Development and Market Position - Kaineng Health is focusing on building its own brands to capture service revenue and user data, which will help create a comprehensive health ecosystem [7][8]. - The company has successfully entered the North American market by acquiring a local brand and plans to establish a production base in the U.S. to enhance supply chain resilience [7][8]. Group 4: Financial Performance - Kaineng Health has maintained an average annual revenue of around 1.6 billion yuan over the past three years, with a cumulative cash distribution of approximately 725 million yuan since its listing [10]. - The company has a payout ratio exceeding 70% over the last three years, indicating strong cash flow and financial stability [10]. Group 5: Leadership and Vision - The founder, Qiu Jianguo, has a history of forward-thinking entrepreneurship, having established Kaineng Health in 2001 when the water purification market was still nascent in China [10][11]. - The current leadership, under Qiu Yaming, aims to innovate and expand the company’s offerings while maintaining the stability of its core business [12].

Core Insights - The forum focused on the latest developments in exosome technology and the progress of local cell technology companies in achieving international compliance for related raw materials [1][3][5] Group 1: Event Overview - The forum, themed "Exploring Cell Messengers Leading the Future of Regeneration," was held in Xi'an and co-hosted by the Xi'an Science and Technology Association and the Xi'an High-tech Zone Management Committee [1][3] - It attracted participation from academic experts, government representatives, clinical researchers, and industry professionals, highlighting the application potential of exosomes in regenerative medicine and disease diagnosis [3][5] Group 2: Key Presentations - Renowned scientist Academician Pei Duanqing provided insights into the development trends, scientific value, and future prospects of exosome technology, emphasizing its potential in regenerative medicine, disease diagnosis, and new drug development [5] - He noted that the standardization and industrialization of exosomes are essential directions for the future [5] Group 3: Industry Developments - The forum announced that local company Medcell Biotechnology's exosome raw materials have received FDA DMF (Drug Master File) registration and have been included in the International Cosmetic Ingredient (INCI) list [5] - This FDA DMF registration indicates that the raw materials meet pharmaceutical-grade regulatory standards, facilitating their application in innovative drug development, while inclusion in the INCI list opens opportunities in the cosmetics sector [5] Group 4: Collaborative Efforts - A ceremony for "Building an Innovative Ecosystem for the Exosome Industry" was held, showcasing the collective commitment of academicians, university representatives, and business leaders to advance exosome technology from laboratory research to industrial application [7] - Collaborating institutions include Shaanxi Normal University and Northwestern Polytechnical University, contributing to the promotion of industry-academia-research cooperation in the biopharmaceutical frontier [7]

Group 1 - The core business revenue composition of Zhongyuan Qihua for the year 2024 is as follows: manufacturing accounts for 70.04%, services account for 27.21%, and other businesses account for 2.76% [1] - Zhongyuan Qihua announced on July 29 that it plans to acquire a 25% stake in Shanghai Zhongyuan Jisheng Cell Technology Co., Ltd. from Shanghai Yanlin Biotechnology Co., Ltd. to enhance operational decision-making efficiency and increase investment in adult health cell storage business [3] - The total assessed value of 100% equity of Shanghai Zhongyuan Jisheng is approximately 15.2783 million yuan, with the agreed transaction price for the 25% stake being around 3.82 million yuan [3]

Core Viewpoint - Zhongyuan Union (600645.SH) aims to enhance operational decision-making efficiency by acquiring a 25% stake in Shanghai Zhongyuan Jisheng Cell Technology Co., Ltd. from Shanghai Yanlin Biotechnology Co., Ltd. for RMB 3.8196 million, thereby making it a wholly-owned subsidiary [1] Group 1: Acquisition Details - The acquisition price for the 25% stake is RMB 3.8196 million [1] - Post-transaction, Shanghai Zhongyuan Jisheng will become a wholly-owned subsidiary of Zhongyuan Union [1] Group 2: Strategic Implications - The transaction is expected to improve operational decision-making efficiency and leverage existing resources such as the cell life experience center and established market channels [1] - The integration aims to enhance collaboration across various business segments and build a complete business loop for adult health cell storage in the East China region [1]